350 related articles for article (PubMed ID: 26013986)
1. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
2. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
Thapi S; Baeg K; Kim MK; Gallagher EJ
Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
[TBL] [Abstract][Full Text] [Related]
3. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
5. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.
Modlin IM; Champaneria MC; Chan AK; Kidd M
Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
7. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
Guo LJ; Wang CH; Tang CW
Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
12. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B; Davis J; Perez E; Lew J; Sola J
Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
[TBL] [Abstract][Full Text] [Related]
13. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment.
Hoffmann KM; Furukawa M; Jensen RT
Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):675-97. PubMed ID: 16253893
[TBL] [Abstract][Full Text] [Related]
14. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
[TBL] [Abstract][Full Text] [Related]
15. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
16. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.
Fraenkel M; Kim M; Faggiano A; de Herder WW; Valk GD;
Endocr Relat Cancer; 2014 Jun; 21(3):R153-63. PubMed ID: 24322304
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic Neuroendocrine Tumors.
Fernandes CJ; Leung G; Eads JR; Katona BW
Gastroenterol Clin North Am; 2022 Sep; 51(3):625-647. PubMed ID: 36153114
[TBL] [Abstract][Full Text] [Related]
18. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes.
Cheema A; Weber J; Strosberg JR
Ann Surg Oncol; 2012 Sep; 19(9):2932-6. PubMed ID: 22350605
[TBL] [Abstract][Full Text] [Related]
19. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.
Hassan MM; Phan A; Li D; Dagohoy CG; Leary C; Yao JC
Int J Cancer; 2008 Aug; 123(4):867-73. PubMed ID: 18491401
[TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
